Insight Molecular Diagnostics (IMDX) AI Stock Analysis

• Market Cap: $175.44M
• Dividend Yield: N/A
• Average Volume (3M): 42.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: 520.87%
• EPS Growth: 36.11%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 28,619,750
• 10 Day Avg. Volume: 47,668
• 30 Day Avg. Volume: 42,754
• PEG Ratio: -0.02
• Price to Book (P/B): -2.53
• Price to Sales (P/S): 16.54
• P/FCF Ratio: -1.47
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: 17.81
• Enterprise Value/Gross Profit: 28.07
• Enterprise Value/Ebitda: -1.24
• 1Y Price Target: $8.50
• Price Target Upside: 25.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $8.00 ▲(17.65% Upside)

Insight Molecular Diagnostics' stock score is primarily influenced by its financial instability and valuation challenges. Despite strong technical momentum and positive earnings call sentiment, the company's high debt and negative cash flows pose significant risks.

Positive Factors

Product Development

The nearing FDA submission for GraftAssure DX indicates progress in product development, potentially enhancing market presence and revenue.

Cash Management

Strong cash management with no debt and substantial cash reserves supports operational stability and strategic investments.

Revenue Growth

Significant revenue growth suggests increasing market demand and successful product adoption, supporting long-term business expansion.

Negative Factors

High Debt Levels

High debt levels indicate financial leverage risk, potentially limiting flexibility and increasing vulnerability to economic shifts.

Profitability Challenges

Ongoing profitability challenges with negative margins highlight operational inefficiencies, impacting long-term financial health.

Clinical Trial Delays

Delays in clinical trial enrollment could postpone product launches and revenue generation, affecting strategic timelines.

Insight Molecular Diagnostics Business Overview & Revenue Model

Company Description

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

How the Company Makes Money

IMDX generates revenue primarily through the sale of its molecular diagnostic tests to clinical laboratories and healthcare facilities. The company's revenue model is built on direct sales of its proprietary assays, which are often reimbursed by insurance providers and government healthcare programs. Additionally, IMDX may engage in partnerships with other healthcare organizations, research institutions, and pharmaceutical companies to develop and commercialize new diagnostic products, further diversifying its income streams. Significant collaborations and licensing agreements can provide upfront payments, milestone payments, and royalties, contributing to the company’s overall financial growth.

Insight Molecular Diagnostics Financial Statement Overview

Summary

Insight Molecular Diagnostics shows revenue growth but faces significant profitability and liquidity challenges. High debt levels and negative cash flows highlight financial instability, posing risks to future operations.

Income Statement

Insight Molecular Diagnostics shows a mixed performance in its income statement. The company has experienced revenue growth, with a notable increase of 10.77% in the TTM period. However, profitability remains a significant challenge, as indicated by negative net profit margins and EBIT margins. The gross profit margin has improved to 63.42% in the TTM, but the company continues to struggle with substantial net losses, reflecting operational inefficiencies.

Balance Sheet

The balance sheet reveals a concerning financial structure with a high debt-to-equity ratio of 3.07 in the TTM, indicating heavy reliance on debt financing. The return on equity is negative, suggesting that the company is not generating sufficient returns on shareholders' investments. The equity ratio is low, pointing to potential financial instability and risk.

Cash Flow

Cash flow analysis shows some positive trends, such as a 48% growth in free cash flow in the TTM. However, the company is still facing negative operating cash flow, which is concerning for its liquidity position. The operating cash flow to net income ratio is negative, indicating that the company is not generating enough cash from its operations to cover its net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.26M	1.88M	1.50M	958.00K	2.20M	1.22M
Gross Profit	2.70M	740.00K	501.00K	78.00K	188.00K	-639.00K
EBITDA	-61.35M	-59.02M	-23.12M	-13.31M	-48.46M	-30.54M
Net Income	-63.42M	-60.66M	-27.78M	-72.90M	-64.10M	-29.93M
Balance Sheet
Total Assets	50.52M	35.08M	74.89M	100.09M	159.56M	55.42M
Cash, Cash Equivalents and Short-Term Investments	24.29M	8.64M	9.43M	20.43M	33.85M	7.82M
Total Debt	3.37M	3.66M	2.87M	3.54M	5.68M	8.63M
Total Liabilities	49.42M	47.35M	49.30M	65.80M	94.35M	21.94M
Stockholders Equity	1.10M	-12.27M	25.59M	34.29M	65.22M	33.48M
Cash Flow
Free Cash Flow	-23.35M	-21.23M	-23.61M	-49.91M	-38.19M	-27.21M
Operating Cash Flow	-23.04M	-20.71M	-23.32M	-45.57M	-35.94M	-25.98M
Investing Cash Flow	-953.00K	-512.00K	-932.00K	-4.34M	-13.96M	-11.75M
Financing Cash Flow	39.03M	20.43M	12.19M	35.81M	78.36M	22.80M

Insight Molecular Diagnostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMDX, the sentiment is Positive. The current price of 6.8 is above the 20-day moving average (MA) of 6.14, above the 50-day MA of 4.41, and above the 200-day MA of 3.27, indicating a bullish trend. The MACD of 0.71 indicates Negative momentum. The RSI at 76.93 is Negative, neither overbought nor oversold. The STOCH value of 80.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMDX.

Insight Molecular Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMDX	58 Neutral	$175.44M	-1.76	-9999.00%	―	520.87%	36.11%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MGNX	45 Neutral	$86.59M	―	-69.71%	―	303.47%	73.70%
ELUT	44 Neutral	$39.00M	-0.87	―	―	-14.92%	72.81%
SRZN	43 Neutral	$107.90M	-0.90	―	―	-63.96%	-28.50%
ATOS	36 Underperform	$109.55M	-3.77	-41.66%	―	―	-8.91%

Insight Molecular Diagnostics Corporate Events

OncoCyte Corp’s Earnings Call: Progress Amid Challenges

The recent earnings call for OncoCyte Corp showcased a generally positive sentiment, highlighting significant advancements in product development and financial stability. However, the company faces challenges due to the government shutdown and slower-than-expected clinical trial enrollment, which could impact their timeline for regulatory approvals.

Insight Molecular Diagnostics Reports Q3 2025 Progress

Insight Molecular Diagnostics Inc. (iMDx) is a pioneering diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes, particularly in the organ transplant sector.

Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study

Study Overview: The GraftAssureDx Study, officially titled ‘Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring,’ aims to determine if the dd-cfDNA test can effectively assess rejection in kidney transplant recipients. This study is significant as it could offer a less invasive alternative to standard graft biopsies, potentially improving patient outcomes and monitoring efficiency.

Insight Molecular Diagnostics Extends Executive Employment Agreement

On September 28, 2025, Insight Molecular Diagnostics Inc. granted stock options to key executives under its Amended and Restated 2018 Equity Incentive Plan, with options vesting over three years. Additionally, on September 29, 2025, the company amended Dr. Ekkehard Schütz’s employment agreement to extend its term indefinitely until termination under existing terms.

The most recent analyst rating on (IMDX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Insight Molecular Diagnostics stock, see the IMDX Stock Forecast page.

Insight Molecular Diagnostics Approves Executive Salary Increases

On September 16, 2025, Insight Molecular Diagnostics Inc. announced that its Board of Directors approved salary increases for key executives. The President and CEO, Joshua Riggs, will see his salary rise from $420,000 to $520,000, while the CFO, Andrea James, will have her salary increased from $341,250 to $441,250, effective September 15, 2025.

The most recent analyst rating on (IMDX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Insight Molecular Diagnostics stock, see the IMDX Stock Forecast page.

OncoCyte Corp’s Earnings Call: Progress Amid Challenges

The recent earnings call for OncoCyte Corp reflects a company making notable strides in its FDA submission process and assay improvements, buoyed by strong engagement with transplant centers and a significant achievement in positive predictive value. Despite these advancements, the company faces challenges in revenue generation and clinical trial enrollment.

IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring?

Study Overview: Insight Molecular Diagnostics Inc. (IMDX) is conducting a study titled ‘GraftAssureDx Study: Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring.’ The study aims to determine if the dd-cfDNA test can effectively assess rejection in kidney transplant recipients, potentially offering a less invasive alternative to traditional graft biopsies.

Insight Molecular Diagnostics Reports Q2 2025 Progress

Insight Molecular Diagnostics Inc., formerly known as OncoCyte Corp, is a diagnostics technology company focused on democratizing access to molecular diagnostic testing, primarily in the field of transplant rejection and oncology. The company is based in Nashville, Tennessee, and is known for its innovative approach to creating kitted assays for localized diagnostic testing.